MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/ms9.0000000000004974

Медицинская библиотека · Annals of medicine and surgery (2012) · 2026

Oral immunotherapy for peanut allergy: a systematic review and meta-analysis.

Waaiz Muhammad, Khan Waniya Badar, Adnan Rimsha, Abid Shiza, Khurshid Muhammad Saad, Karim Jamal Nasir, Khan Saira Jahangir, Javed Eman, Fahim Syeda Laiba, Kumari Verkha, Tabassum Muzainah, Muhammad Qurat Ul Ain, Bhattarai Pratik

СтатьяПеревод в очереди

Аннотация

BACKGROUND AND

OBJECTIVES

Food allergy, particularly peanut allergy, is a significant and growing health concern, especially in high-income countries. Affecting 2% of children and 1% of adults, peanut allergy is a chronic condition that severely impacts quality of life. The standard treatment remains allergen avoidance, though oral immunotherapy (OIT) has emerged as a potential strategy for desensitization. This systematic review and meta-analysis aims to evaluate the efficacy and safety of peanut oral immunotherapy (POIT) based on randomized controlled trials (RCTs).

METHODS

A systematic review and meta-analyses were conducted following PRISMA guidelines. Eligible studies included double-blind RCTs evaluating POIT versus placebo or avoidance. Databases such as PubMed, Google Scholar, Cochrane-Controlled Register of Trials, and ClinicalTrials.gov were searched. Risk of bias was assessed using the Cochrane Risk of Bias tool (ROB2), and statistical analysis was performed using the RevMan software.

RESULTS

A total of 20 studies with 2161 participants (median age: 8.6 years) were included. POIT demonstrated a significant increase in desensitization rates (RR = 7.25, 95% CI: 2.66-19.79, P = 0.0001). However, POIT was also associated with increased risks of anaphylaxis (RR = 2.27, 95% CI: 1.48-3.47, P = 0.0002) and epinephrine use (RR = 2.05, 95% CI: 1.35-3.12, P = 0.0008). Adverse effects such as gastrointestinal symptoms, respiratory events, and skin abnormalities were more frequent in the POIT group, leading to a higher treatment discontinuation rate (RR = 2.50, 95% CI: 1.20-5.21, P = 0.01).

CONCLUSION

POIT is effective in inducing desensitization in peanut-allergic individuals but carries significant risks, including an increased likelihood of anaphylaxis and adverse events. These findings reinforce previous meta-analyses and highlight the need for individualized risk-benefit assessments in clinical practice. Further research is required to optimize treatment protocols and improve patient safety.

Для цитирования: Waaiz Muhammad, Khan Waniya Badar, Adnan Rimsha, Abid Shiza, Khurshid Muhammad Saad, Karim Jamal Nasir, Khan Saira Jahangir, Javed Eman, Fahim Syeda Laiba, Kumari Verkha, Tabassum Muzainah, Muhammad Qurat Ul Ain, Bhattarai Pratik. Oral immunotherapy for peanut allergy: a systematic review and meta-analysis.. Annals of medicine and surgery (2012). 2026. DOI: 10.1097/ms9.0000000000004974.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.